Enliven Therapeutics Ownership | Who Owns Enliven Therapeutics?

Enliven Therapeutics Ownership Summary

Enliven Therapeutics is owned by 128.23% institutional investors, 6.23% insiders. Fmr is the largest institutional shareholder, holding 15.96% of ELVN shares. Polar Capital Healthcare Opports Inc is the top mutual fund, with 5.05% of its assets in Enliven Therapeutics shares.

ELVN Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Enliven Therapeutics	128.23%	6.23%	-34.46%
Sector	Healthcare Stocks	50.47%	12.28%	37.25%
Industry	Biotech Stocks	49.08%	12.05%	38.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Fmr	10.03M	15.96%	$508.77M
Orbimed advisors	6.78M	10.79%	$343.91M
Polar capital	6.43M	10.24%	$326.35M
Blackrock funding, inc. /de	4.36M	6.94%	$221.25M
Vestal point capital, lp	4.00M	6.37%	$203.00M
Commodore capital lp	3.27M	5.21%	$166.21M
Price t rowe associates inc /md/	2.90M	4.62%	$147.37M
Vanguard group	2.80M	4.51%	$43.15M
Vanguard capital management	2.57M	4.09%	$130.38M
Citadel advisors	2.07M	3.29%	$105.00M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Commodore capital lp	3.27M	9.90%	$166.21M
Orbimed advisors	6.78M	6.41%	$343.91M
Fairmount funds management	1.86M	6.22%	$94.17M
Tri locum partners lp	866.72K	5.41%	$43.99M
First turn management	954.36K	5.18%	$48.43M
Vestal point capital, lp	4.00M	4.74%	$203.00M
Avidity partners management lp	550.00K	4.47%	$27.91M
First light asset management	1.36M	4.20%	$69.06M
Exome asset management	100.20K	3.14%	$5.09M
Stempoint capital lp	346.91K	3.03%	$17.61M

Top Buyers

Holder	Shares	% Assets	Change
Fmr	10.03M	0.02%	3.20M
Price t rowe associates inc /md/	2.90M	0.01%	2.81M
Polar capital	6.43M	0.77%	1.36M
First light asset management	1.36M	4.20%	1.16M
Adage capital partners gp	1.08M	0.08%	1.08M

Top Sellers

Holder	Shares	% Assets	Change
Janus henderson group	11.00K	0.00%	-1.66M
Point72 asset management	-	-	-1.50M
Capital research global investors	-	-	-1.30M
Vr adviser	526.33K	0.81%	-1.20M
Orbimed advisors	6.78M	6.41%	-1.18M

New Positions

Holder	Shares	% Assets	Change	Value
Adage capital partners gp	1.08M	0.08%	1.08M	$54.98M
Samlyn capital	912.64K	0.75%	912.64K	$46.32M
Tri locum partners lp	866.72K	5.41%	866.72K	$43.99M
Silverarc capital management	489.38K	2.58%	489.38K	$24.84M
Sixth street partners management company	424.44K	0.00%	424.44K	$21.54M

Sold Out

Holder	Change
Mai capital management	-7.00
Td capital management	-16.00
Stephens consulting	-20.00
Rockefeller capital management	-25.00
Allworth financial lp	-39.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2026	218	21.11%	80,527,066	29.07%	128	1.06%	153	18.60%	48	45.45%
Mar 31, 2026	90	-29.13%	11,947,495	-80.85%	21	0.21%	64	-1.54%	17	-62.22%
Dec 31, 2025	85	-36.09%	19,456,209	-67.24%	31	0.34%	42	-46.84%	34	13.33%
Sep 30, 2025	52	-57.72%	9,174,149	-84.56%	17	0.14%	34	-58.02%	10	-56.52%
Jun 30, 2025	122	0.83%	59,425,065	19.12%	114	1.14%	80	23.08%	23	-30.30%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Polar Capital Healthcare Opports Inc	3.61M	5.05%	813.74K
Polar Capital Biotech S Inc	2.56M	3.58%	524.62K
Vanguard Total Stock Mkt Idx Inv	1.88M	2.64%	276.54K
Vanguard Morn Total Stk Mkt Idx Investor	1.88M	2.64%	276.54K
Fidelity Small Cap Growth	1.38M	1.93%	38.20K
Fidelity Select Health Care	1.36M	1.91%	244.92K
iShares Russell 2000 ETF	1.09M	1.49%	-19.39K
US Small-Cap Growth II Equity Comp	807.33K	1.13%	807.33K
T. Rowe Price New Horizons	807.33K	1.13%	807.33K
Fidelity Stock Selector Small Cap	773.81K	1.08%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Aug 04, 2026	Derynck Mika K	-	Sell	$9.56M
Jul 17, 2026	Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sell	$19.00K
Jul 17, 2026	Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sell	$16.19K
Jul 17, 2026	Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sell	$134.14K
Jul 17, 2026	Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sell	$140.82K

Insider Transactions Trends

Date	Buy	Sell
2026 Q3	-	13
2026 Q2	-	21
2026 Q1	-	21
2025 Q4	-	11
2025 Q3	-	28

ELVN Ownership FAQ

Who Owns Enliven Therapeutics?

Enliven Therapeutics shareholders are primarily institutional investors at 128.23%, followed by 6.23% insiders and -34.46% retail investors. The average institutional ownership in Enliven Therapeutics's industry, Biotech Stocks , is 49.08%, which Enliven Therapeutics exceeds.

Who owns the most shares of Enliven Therapeutics?

Enliven Therapeutics’s largest shareholders are Fmr (10.03M shares, 15.96%), Orbimed advisors (6.78M shares, 10.79%), and Polar capital (6.43M shares, 10.24%). Together, they hold 36.99% of Enliven Therapeutics’s total shares outstanding.

Does Blackrock own Enliven Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Enliven Therapeutics.

Who is Enliven Therapeutics’s biggest shareholder by percentage of total assets invested?

Commodore capital lp is Enliven Therapeutics’s biggest shareholder by percentage of total assets invested, with 9.90% of its assets in 3.28M Enliven Therapeutics shares, valued at 166.21M$.

Who is the top mutual fund holder of Enliven Therapeutics shares?

Polar Capital Healthcare Opports Inc is the top mutual fund holder of Enliven Therapeutics shares, with 5.05% of its total shares outstanding invested in 3.61M Enliven Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools